4.6700
+0.3900
+(9.11%)
At close: January 13 at 4:00:01 PM EST
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Guido Baechler | CEO & Executive Director | -- | -- | 1965 |
| Mr. William J. Caragol CPA | Chief Financial Officer | -- | -- | 1967 |
| Dr. Christopher Von Torne P.M.P., Ph.D. | Chief Operating Officer | -- | -- | 1972 |
| Dr. Frank Krieg-Schneider | Chief Technology Officer | -- | -- | 1962 |
| Dr. Moritz Eidens Ph.D. | Chief Science Officer & Executive Director | -- | -- | 1984 |
| Stefan Erlach | Head of Human Resources | -- | -- | -- |
| Mr. Philipp Freese | Chief Business Officer | -- | -- | 1983 |
Mainz Biomed N.V.
- Sector:
- Healthcare
- Industry: Diagnostics & Research
- Full Time Employees:
- 65
Description
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. It has a collaboration agreement with Thermo Fisher Scientific Inc. for the development of colorectal cancer screening product. The company was founded in 2008 and is based in Mainz, Germany.
Corporate Governance
Mainz Biomed N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
April 7, 2025 at 12:30 PM UTC - April 11, 2025 at 12:30 PM UTC
Mainz Biomed N.V. Earnings Date
Recent Events
Related Tickers
DGX Quest Diagnostics Incorporated
154.02
+1.47%
CSTL Castle Biosciences, Inc.
26.15
-13.55%
TTOO T2 Biosystems, Inc.
0.3200
0.00%
APDN Applied DNA Sciences, Inc.
0.1934
-2.18%
CHEK Check-Cap Ltd.
1.5000
-1.96%
GH Guardant Health, Inc.
38.10
+3.80%
ISPC iSpecimen Inc.
2.6800
0.00%
STIM Neuronetics, Inc.
2.3400
+36.84%
PRPH ProPhase Labs, Inc.
0.6490
0.00%
PSNL Personalis, Inc.
5.35
-4.29%